Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference

Rhea-AI Summary

Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotech company focused on molecular glue degrader (MGD)-based medicines, announced its participation in the upcoming Jefferies Global Healthcare Conference. CEO Markus Warmuth will engage in a fireside chat on June 4, 2025, at 12:50 p.m. EDT. The presentation will be available through webcast on the company's investor relations website, with a replay accessible for 30 days afterward.

News Market Reaction

+1.75%

1 alert

+1.75% News Effect

On the day this news was published, GLUE gained 1.75%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 12:50 p.m. EDT.

A webcast of the fireside chat will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com, and an archived version will be made available for 30 days following the presentation.

About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans autoimmune and inflammatory diseases, oncology, and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com.

Investors
Andrew Funderburk
ir@monterosatx.com

Media
Cory Tromblee, Scient PR
media@monterosatx.com

FAQ

When is Monte Rosa Therapeutics (GLUE) presenting at the Jefferies Healthcare Conference 2025?

Monte Rosa Therapeutics will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 12:50 p.m. EDT.

Who will represent Monte Rosa Therapeutics (GLUE) at the Jefferies Conference 2025?

Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics, will participate in a fireside chat at the conference.

How can investors access Monte Rosa Therapeutics' (GLUE) Jefferies Conference presentation?

The presentation can be accessed via webcast through the 'Events & Presentations' section of Monte Rosa's website at ir.monterosatx.com, with a replay available for 30 days.

What is Monte Rosa Therapeutics' (GLUE) main business focus?

Monte Rosa Therapeutics is a clinical-stage biotechnology company that develops novel molecular glue degrader (MGD)-based medicines.